## (1) MAY AUTHORIZE:

- (I) THE MODIFICATION, CONTINUATION, AND DISCONTINUATION OF DRUG THERAPY UNDER WRITTEN, DISEASE-STATE SPECIFIC PROTOCOLS:
  - (II) THE ORDERING OF LABORATORY TESTS: AND
- (III) OTHER PATIENT CARE MANAGEMENT MEASURES RELATED TO MONITORING OR IMPROVING THE OUTCOMES OF DRUG OR DEVICE THERAPY: AND
- (2) MAY NOT AUTHORIZE ACTS THAT EXCEED THE SCOPE OF PRACTICE OF THE PARTIES TO THE THERAPY MANAGEMENT CONTRACT.
- (B) A PROTOCOL SHALL PROHIBIT THE SUBSTITUTION OF A CHEMICALLY DISSIMILAR DRUG PRODUCT BY THE PHARMACIST FOR THE PRODUCT PRESCRIBED BY THE PHYSICIAN, UNLESS PERMITTED IN THE THERAPY MANAGEMENT CONTRACT. 12–6A–07.
- (A) A THERAPY MANAGEMENT CONTRACT SHALL APPLY ONLY TO CONDITIONS FOR WHICH PROTOCOLS HAVE BEEN APPROVED BY THE BOARD OF PHYSICIAN QUALITY ASSURANCE AND THE BOARD OF PHARMACY UNDER THE REGULATIONS ADOPTED UNDER THIS SUBTITLE.
- (B) A THERAPY MANAGEMENT CONTRACT SHALL TERMINATE ONE YEAR FROM THE DATE OF ITS SIGNING, UNLESS RENEWED BY THE LICENSED PHYSICIAN, LICENSED PHARMACIST, AND PATIENT.
  - (C) A THERAPY MANAGEMENT CONTRACT SHALL INCLUDE:
- (1) A STATEMENT THAT NONE OF THE PARTIES INVOLVED IN THE THERAPY MANAGEMENT CONTRACT HAVE BEEN COERCED, GIVEN ECONOMIC INCENTIVES, EXCLUDING NORMAL REIMBURSEMENT FOR SERVICES RENDERED, OR INVOLUNTARILY REQUIRED TO PARTICIPATE;
- (2) NOTICE TO THE PATIENT INDICATING HOW THE PATIENT MAY TERMINATE THE THERAPY MANAGEMENT CONTRACT;
- (3) A PROCEDURE FOR PERIODIC REVIEW BY THE PHYSICIAN, OF THE DRUGS MODIFIED PURSUANT TO THE AGREEMENT OR CHANGED WITH THE CONSENT OF THE PHYSICIAN; AND
- (4) REFERENCE TO AN APPROVED PROTOCOL, WHICH WILL BE PROVIDED TO THE PATIENT UPON REQUEST.
- (D) ANY PARTY TO THE THERAPY MANAGEMENT CONTRACT MAY TERMINATE THE CONTRACT AT ANY TIME.
- (E) FEES PAID TO THE BOARD OF PHYSICIAN QUALITY ASSURANCE AND BOARD OF PHARMACY RELATED TO THERAPY MANAGEMENT SHALL BE ESTABLISHED IN REGULATIONS.